Insider Selling: Natera, Inc. (NASDAQ:NTRA) Insider Sells 2,700 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) insider Jonathan Sheena sold 2,700 shares of Natera stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $113.82, for a total value of $307,314.00. Following the sale, the insider now directly owns 299,441 shares in the company, valued at approximately $34,082,374.62. The sale was disclosed in a document filed with the SEC, which is available at this link.

Jonathan Sheena also recently made the following trade(s):

• On Monday, July 1st, Jonathan Sheena sold 2,700 shares of Natera stock. The stock was sold at an average price of $108.87, for a total value of $293,949.00.
• On Tuesday, June 18th, Jonathan Sheena sold 2,700 shares of Natera stock. The stock was sold at an average price of $109.66, for a total value of $296,082.00.
• On Thursday, May 23rd, Jonathan Sheena sold 1,000 shares of Natera stock. The stock was sold at an average price of $108.30, for a total value of $108,300.00.

Natera Trading Down 0.4 %

Shares of Natera stock traded down $0.52 during trading on Wednesday, reaching $118.50. 830,494 shares of the company were exchanged, compared to its average volume of 1,401,661. The company has a quick ratio of 3.98, a current ratio of 4.12 and a debt-to-equity ratio of 0.36. Natera, Inc. has a twelve month low of $36.90 and a twelve month high of $119.90. The business has a 50-day moving average price of $108.46 and a 200-day moving average price of $96.27. The firm has a market capitalization of $14.55 billion, a price-to-earnings ratio of -37.98 and a beta of 1.48.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.39. Natera had a negative return on equity of 49.72% and a negative net margin of 30.24%. The business had revenue of $413.35 million during the quarter, compared to analysts’ expectations of $343.00 million. During the same period in the previous year, the firm earned ($0.97) earnings per share. The firm’s quarterly revenue was up 58.1% compared to the same quarter last year. Sell-side analysts anticipate that Natera, Inc. will post -2.43 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Itau Unibanco Holding S.A. bought a new stake in shares of Natera in the second quarter valued at about $28,000. Principal Securities Inc. bought a new stake in Natera during the fourth quarter worth about $32,000. GAMMA Investing LLC raised its holdings in Natera by 50.0% during the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after acquiring an additional 108 shares in the last quarter. YHB Investment Advisors Inc. bought a new stake in Natera during the first quarter worth about $36,000. Finally, Oliver Lagore Vanvalin Investment Group raised its holdings in Natera by 109.3% during the fourth quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock worth $47,000 after acquiring an additional 389 shares in the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms recently commented on NTRA. Piper Sandler raised their target price on Natera from $120.00 to $150.00 and gave the stock an “overweight” rating in a research report on Tuesday. BTIG Research raised their target price on Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Jefferies Financial Group started coverage on Natera in a research report on Monday, June 3rd. They issued a “buy” rating and a $142.00 price objective for the company. Stephens reiterated an “overweight” rating and issued a $125.00 price objective on shares of Natera in a research report on Friday, August 9th. Finally, Canaccord Genuity Group lifted their price objective on Natera from $100.00 to $130.00 and gave the company a “buy” rating in a research report on Friday, May 10th. One investment analyst has rated the stock with a sell rating and fifteen have given a buy rating to the stock. According to MarketBeat.com, Natera currently has an average rating of “Moderate Buy” and a consensus target price of $119.07.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.